SARS-CoV-2 Treatment & Prevention Approaches

Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 17
Format: PDF
Product Line: Competitor Analysis
Product Code: LMCA0181
Release Date: March of 2020

Competitor Analysis: SARS-CoV-2 Treatment & Prevention Approaches

This Competitive Intelligence report about SARS-CoV-2 Treatment & Prevention Approaches describes the landscape of industry-driven approaches to evaluate existing, discover novel treatments and vaccines for COVID-19.

COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no licensed vaccine, treatment or cure for COVID-19. Industry alone or collaboration with govermnent agencies or non-governmental organizations (NGOs) have started to searh for safe and effective treatments and vaccines to fight the novel 2019 coronavirus (2019-nCoV or SARS-CoV-2) causing COVID-19 disease.

This report includes a compilation of industry-driven projects in research and development of treatments and vaccines for COVID-19. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01